"Juno investors would also do well to track the IPO proceeds carefully and consider the amounts of options granted to management, some of whom were behind the cell therapy play Dendreon, which recently collapsed under its debts." $ Juno Therapeutics (JUNO)$ $Dendreon(DNDN)$